Insight Molecular Diagnostics Inc. Common Stock (IMDX) is a publicly traded Healthcare sector company. As of May 21, 2026, IMDX trades at $6.04 with a market cap of $205.04M and a P/E ratio of -3.56. IMDX moved +0.00% today. Year to date, IMDX is -17.14%; over the trailing twelve months it is flat. Its 52-week range spans $2.33 to $8.51. Analyst consensus is buy with an average price target of $10.50. Rallies surfaces IMDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Recent IMDX insider activity includes BROADWOOD PARTNERS, L.P. bought 250.92K, BROADWOOD PARTNERS, L.P. bought 38.88K, BROADWOOD PARTNERS, L.P. bought 280.38K, BROADWOOD PARTNERS, L.P. bought 40.69K, and BROADWOOD PARTNERS, L.P. bought 40.11K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
| Metric | Value |
|---|---|
| Price | $6.04 |
| Market Cap | $205.04M |
| P/E Ratio | -3.56 |
| EPS | $-1.65 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.51 |
| 52-Week Low | $2.33 |
| Volume | 1.53K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.05M |
| Net Income | $-50.22M |
| Gross Margin | 56.67% |
3 analysts cover IMDX: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.50.